Inquiry Now
QF PCR for Trisomy detection [Fluorescent primer based; PCR-Fragment analysis; require Sanger Sequencing Platform]
Unveiling the Future of Trisomy Detection: Introducing Our Semi-Quantitative Fluorescent PCR (QF PCR) Assay
Step into the forefront of genetic screening with our revolutionary Semi-Quantitative Fluorescent PCR (QF PCR) assay, poised to redefine trisomy detection with unparalleled accuracy and efficiency. Leveraging the power of PCR-fragment analysis on a Sanger sequencing platform, this cutting-edge technology offers a sophisticated solution for comprehensive trisomy assessment, empowering clinicians and researchers with invaluable insights into fetal health.
The Evolution of Trisomy Detection
Trisomies, characterized by the presence of an extra chromosome, are among the most common chromosomal abnormalities affecting human fetuses. Timely and accurate detection of trisomies is essential for informed decision-making during pregnancy, ensuring the best possible outcomes for both mother and child. Our QF PCR assay represents a significant leap forward in trisomy screening, combining the sensitivity of PCR with the precision of fragment analysis on a trusted Sanger sequencing platform.
Unrivaled Precision with Semi-Quantitative Analysis
Unlike traditional qualitative PCR methods, our semi-quantitative approach provides a nuanced understanding of trisomy status by measuring the relative abundance of target DNA fragments. This enables precise quantification of chromosomal abnormalities, allowing for more informed risk assessment and personalized counseling for expectant parents. With our QF PCR assay, you can confidently identify trisomies with enhanced accuracy and reliability, guiding clinical decision-making with confidence and clarity.
Key Advantages of Our Assay
- High Sensitivity: Detects trisomies with exceptional sensitivity, even at low fetal DNA concentrations, for early and reliable screening.
- Semi-Quantitative Analysis: Quantifies target DNA fragments to provide a more comprehensive assessment of trisomy status, facilitating informed risk stratification.
- Versatile Platform: Compatible with standard Sanger sequencing platforms, ensuring seamless integration into existing laboratory workflows.
- Robust Performance: Delivers consistent and reproducible results, minimizing variability and maximizing confidence in clinical interpretation.
- Comprehensive Support: Backed by our team of experts, who provide ongoing assistance and guidance to optimize assay performance and interpretation.
Empowerment Through Knowledge
At the heart of our QF PCR assay is a commitment to empowering healthcare professionals and expectant parents with the knowledge they need to make informed decisions about pregnancy care. By offering a sophisticated yet accessible tool for trisomy detection, we aim to revolutionize prenatal screening and usher in a new era of personalized medicine.
Experience the Future of Trisomy Detection
Join us in shaping the future of prenatal care with our Semi-Quantitative Fluorescent PCR (QF PCR) assay. Contact us today to learn more about how our innovative technology can elevate your practice and transform the way you approach trisomy screening. Together, let’s embark on a journey towards healthier pregnancies and brighter futures for families worldwide.
- Semi Quantitative
ORDER INFORMATION
REF | PACKAGE |
---|---|
QFFP/WBB/25 | 25 reactions |
QFFP/WBB/100 | 100 reactions |
INTENDED USER | For research use only and NOT intended for in vitro diagnostics. |
TECHNOLOGY | Fluorescent primer based; PCR-Fragment analysis; require Sanger Sequencing Platform |
TYPE OF ANALYSIS | Semi Qualitative |
TARGET SEQUENCE | Aneuploidies in chromosomes 13, 18, 21, X, and Y |
Controls | Positive control |
VALIDATED SPECIMAN | Whole blood |
STORAGE | -20 ± 5 °C |
INSTRUMENTS | COMPATIBLE WITH A WIDE RANGE OF CONVENTIONAL PCR DEVICES AND ABI-DNA CAPILLARY ELECTROPHORESIS SEQUENCING |